This retrospective multicenter study aimed to evaluate the effectiveness of programmed death receptor-1 (PD-1)-blockade as a consolidation treatment for patients with RR-HL at high risk of ASCT failure. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.